⌕
Viridian Therapeutics · VRDN · Nasdaq
Tenet 43 · Weak
Compare
$30.87+1.28%At closeTenet 43 · Weak
$30.87+0.39 (+1.28%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Viridian Therapeutics (VRDN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 9, 2026 · 14:01 ET
Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans Transcript

Viridian Therapeutics, Inc. ( VRDN ) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans November 9, 2026 8:00 AM EST Company Participants Greg Rossino Stephen Mahoney - CEO, President & Director Radh…

● BenzingaNov 9, 2026 · 11:55 ET
Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing

Viridian Therapeutics Inc. (NASDAQ:VRDN) reported positive Phase 1 clinical trial results for VRDN-008, highlighting its pharmacokinetic and pharmacodynamic profile as a potential best-in-class subcutaneous treatment for…

● Business WireNov 9, 2026 · 07:01 ETCOMPANY'S OWN WORDS
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare disea…

● Business WireNov 6, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare dis…

● Zacks Investment ResearchNov 6, 2026 · 10:56 ET
Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive tre…

● Seeking AlphaNov 5, 2026 · 08:10 ET
Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead

Viridian Therapeutics delivered a strong Q3, with Lumvoa net sales of $24.7 million, far surpassing consensus expectations. Competition is intensifying with Roche's Enspryng entering the TED market, but I see Lumvoa as w…

● MarketBeatNov 4, 2026 · 17:15 ET
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call

Viridian Therapeutics NASDAQ: VRDN reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment's first quarter on the market, with more than 100 patients having received at least one in…

● Seeking AlphaNov 4, 2026 · 14:04 ET
Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript

Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 4, 2026 · 09:56 ET
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to a loss of $0.34 per share a year ago.…

● Business WireNov 4, 2026 · 07:01 ETCOMPANY'S OWN WORDS
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare dis…

● GlobeNewsWireOct 23, 2026 · 07:59 ETCOMPANY'S OWN WORDS
Viridian Intersects 15m of 1.1% CuEq in 1.5km Step-Out Drilling at Kraken Main

OTTAWA, Ontario, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) (“Viridian” or the “Company”) has intersected 15.05 metres at 1.09% CuEq within 40.8 metres at 0.63% CuEq, approximately …

● Business WireOct 20, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare dis…

● Defense WorldSep 30, 2026 · 06:44 ET
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen analysts that are covering the stock, Marketbeat Ratings reports. One investment a…

● Seeking AlphaSep 17, 2026 · 10:46 ET
Viridian Therapeutics: Two Products, One Commercial Buildout

Viridian Therapeutics shifts focus from regulatory risk to launch execution after FDA approval of Lumvoa for thyroid eye disease (TED). VRDN aims to leverage its commercial infrastructure for both Lumvoa and investigatio…

● GlobeNewsWireSep 8, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main

OTTAWA, Ontario, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) reports initial assay results from its 2026 drill program at the Kraken Main Zone in Labrador.…

● Defense WorldSep 8, 2026 · 04:49 ET
27,472 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Jupiter Topco LLC

Jupiter Topco LLC acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commissio…

● Business WireSep 2, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare dis…

● Defense WorldAug 27, 2026 · 03:34 ET
Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN

Algert Global LLC lowered its position in Viridian Therapeutics, Inc. (NASDAQ: VRDN) by 14.5% in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).…

● Defense WorldAug 24, 2026 · 03:54 ET
Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN

Deutsche Bank AG bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 482,875 shares of the c…

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.